CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India
CytoMed Therapeutics Limited - Ordinary Shares (GDTC)
Company Research
Source: GlobeNewswire
SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology (termed “TCB-002”) of TC BioPharm Limited (“TCBL”), a subsidiary of TC BioPharm (Holdings) PLC (OTC:TCBPY). This follows CytoMed’s announcement on October 14, 2025 regarding its proposed acquisition of potentially synergistic assets from TCBL. TCB-002 will complement CytoMed’s strategy to establish a next-generation non-viral allogeneic gamma delta T cell immunotherapy platform to treat cancer and autoimmune diseases. The acquired technology for TCB-002 has previously completed a Phase I cl
Show less
Read more
Impact Snapshot
Event Time:
GDTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDTC alerts
High impacting CytoMed Therapeutics Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GDTC
News
- CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical ProgressGlobeNewswire
- CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capitalGlobeNewswire
- CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in MalaysiaGlobeNewswire
- CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China StrategyGlobeNewswire
GDTC
Sec Filings
- 1/28/26 - Form 6-K
- 1/13/26 - Form 6-K
- 12/8/25 - Form 6-K
- GDTC's page on the SEC website